Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03846128 | Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients…(BIOSUNTOX) | — | terminated | Feb 19, 2019 | University Hospital, Rouen | Changes in the indication for Sunitinib in metastatic renal cell carcinoma, which have led to a… | Other (stated, no rule matched) |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using… | Phase 2 | terminated | Jul 16, 2010 | Cancer Trials Ireland | not stated | Not stated |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant…(DICE) | Phase 2 | terminated | Mar 11, 2019 | Cancer Trials Ireland | Insufficient accrual | Enrollment / accrual |
| NCT07000344 | A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen… | N/A | terminated | Jun 2, 2025 | Peking Union Medical College Hospital | Results failed to achieve the anticipated effect. | Other (stated, no rule matched) |
| NCT07035067 | Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and… | — | terminated | Jun 24, 2025 | PeriPharm | Recruitment | Enrollment / accrual |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade…(exBOND) | Phase 2 | withdrawn | May 21, 2014 | CG Oncology, Inc. | Change in trial design | Other (stated, no rule matched) |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | Phase 1 | terminated | Apr 21, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns. | Safety / toxicity |
| NCT03894215 | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in… | Phase 2 | terminated | Mar 28, 2019 | Agenus Inc. | Sponsor strategic decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable… | Phase 2 | terminated | Sep 8, 2021 | M.D. Anderson Cancer Center | PI request | Other (stated, no rule matched) |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT03420963 | Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and… | Phase 1 | terminated | Feb 5, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal… | Phase 2 | terminated | May 27, 2021 | M.D. Anderson Cancer Center | Withdrawal of funding from the supporter (Mirati Therapeutics) | Funding |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone…(CONTACT-03) | Phase 3 | terminated | Apr 8, 2020 | Hoffmann-La Roche | As the study did not meet it's primary endpoint a decision was made to terminate the study. | Other (stated, no rule matched) |
| NCT03922776 | Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After…(TILsOV) | N/A | terminated | Apr 22, 2019 | Centre Oscar Lambret | End of recruiting period | Enrollment / accrual |
| NCT04016142 | Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced…(ACCRAPAN) | Phase 2 | terminated | Jul 11, 2019 | Centre Oscar Lambret | The study is discontinued because of recruitment failure, and for strategic reason (competitive… | Enrollment / accrual |
| NCT02478112 | Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity…(BioPro-RCMI) | N/A | terminated | Jun 23, 2015 | Centre Oscar Lambret | Lack of recruitment | Enrollment / accrual |
| NCT03360721 | Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic… | Phase 2 | terminated | Dec 4, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative…(NeuroPrevPTSD) | Phase 2 | terminated | Aug 29, 2018 | Centre Oscar Lambret | Lack of recruitment and of study staff | Enrollment / accrual |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | N/A | withdrawn | Dec 16, 2025 | The Royal Wolverhampton Hospitals NHS Trust | Study no longer going ahead | Other (stated, no rule matched) |
| NCT04179864 | A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With…(CELLO-1) | Phase 1 / Phase 2 | terminated | Nov 27, 2019 | Epizyme, Inc. | The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in… | Safety / toxicity |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 3, 2020 | Sun Yat-sen University | Five patients were enrolled in the study, but no treatment response was observed and all the… | Efficacy / futility |
| NCT06860386 | Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC | Phase 2 | suspended | Mar 6, 2025 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02946996 | Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in… | Phase 2 | terminated | Oct 27, 2016 | Medical University of South Carolina | Investigator retired from clinical practice prior to enrollment goal being met. | Investigator |
| NCT06114940 | Perioperative TORIPALIMAB Plus LENVATINIB in Patients With Renal Cell Carcinoma…(PLUTO) | Phase 2 | terminated | Nov 2, 2023 | Jinling Hospital, China | Involving changes to the primary endpoint, it is difficult to unify the evaluation criteria for… | Other (stated, no rule matched) |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | Genmab | Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment | Enrollment / accrual |
| NCT04243473 | Biopsy Collection for Men Undergoing Brachytherapy for Prostate Cancer | — | withdrawn | Jan 28, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study team decided to not move forward with enrolling patients because funding was not… | Enrollment / accrual |
| NCT04895748 | DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in… | Phase 1 | terminated | May 20, 2021 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05676463 | MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer | Phase 2 | terminated | Jan 9, 2023 | Thomas Jefferson University | Loss of required MRI resources needed to conduct protocol-specified procedures | Other (stated, no rule matched) |
| NCT07211204 | Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular… | N/A | withdrawn | Oct 7, 2025 | Timser SAPI de CV | The study did not start, i.e., no participants were enrolled, because the Mexican Regulatory… | Enrollment / accrual |
| NCT05192837 | Preoperative Smoking Cessation in Patients Undergoing Surgery(PORTICO) | N/A | terminated | Jan 14, 2022 | Luzerner Kantonsspital | The study is being terminated prematurely due to insufficient participant recruitment. | Enrollment / accrual |
| NCT00999960 | Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator(PERLE) | N/A | terminated | Oct 22, 2009 | Assistance Publique - Hôpitaux de Paris | lack of inclusion | Other (stated, no rule matched) |
| NCT06047509 | Focal Laser Ablation of Prostate Cancer: A Feasibility Study Using MRI/US Image Fusion… | N/A | terminated | Sep 21, 2023 | Jonsson Comprehensive Cancer Center | low accrual | Enrollment / accrual |
| NCT05014295 | Patient Recall of Cancer Screening and Diagnosis | N/A | withdrawn | Aug 20, 2021 | Case Comprehensive Cancer Center | Staffing unavailability | Other (stated, no rule matched) |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT02744287 | Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With… | Phase 1 | terminated | Apr 20, 2016 | Regeneron Pharmaceuticals | Due to a Dose Limiting Toxicity. | Safety / toxicity |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT04876651 | The Present Study Aims to Compare Patients Who Receive the Investigational Product… | Phase 3 | terminated | May 6, 2021 | Telix Pharmaceuticals (Innovations) Pty Ltd | Telix is conducting a separate Phase 3 clinical trial - ProstACT Global NCT06520345- to expedite… | Other (stated, no rule matched) |
| NCT03165721 | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in… | Phase 2 | terminated | May 24, 2017 | National Cancer Institute (NCI) | Study closed to enrollment due to low accrual. | Enrollment / accrual |
| NCT03027986 | Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men…(PROTOMEN) | N/A | withdrawn | Jan 23, 2017 | University Hospital, Rouen | Study population didn't exist yet | Other (stated, no rule matched) |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT05487859 | Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Aug 4, 2022 | University of Alabama at Birmingham | due to overall cost of the study | Other (stated, no rule matched) |
| NCT06026332 | ADSTILADRIN Early Utilization and Outcomes in the Real World Setting(ABLE-41) | — | terminated | Sep 7, 2023 | Ferring Pharmaceuticals | An internal audit identified major inconsistencies and missing data in key registry fields,… | Other (stated, no rule matched) |
| NCT05928806 | Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial(ARCITECT) | Phase 2 | suspended | Jul 3, 2023 | Michael B. Atkins, MD | Interim Analysis | Efficacy / futility |
| NCT06716853 | A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With…(TEM-GU) | Phase 1 / Phase 2 | terminated | Dec 4, 2024 | Genenta Science | Persistent challenges have been encountered in patient recruitment, difficulty in identifying a… | Safety / toxicity |
| NCT04754425 | Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer | Phase 2 | terminated | Feb 15, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT07226102 | Virtual Mental Health Intervention to Address Fear of Progression for Women With High… | N/A | withdrawn | Nov 10, 2025 | City of Hope Medical Center | slow accrual | Enrollment / accrual |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant… | Phase 1 / Phase 2 | terminated | Mar 7, 2023 | Sonnet BioTherapeutics | Failed to meet efficacy endpoint criteria, despite lack of safety concerns | Safety / toxicity |
| NCT05850663 | Quality of Life Assessment of Radiotherapy in Recurrent Head and Neck Cancer | N/A | withdrawn | May 9, 2023 | University of Oklahoma | Study withdrawn due to lack of accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 14, 2026source: clinicaltrials